Infinitopes is a **Cancer Research UK (CRUK)-led spinout from Oxford University**. We are also backed by Cancer Research Institute NY, and leading British investors, Octopus Ventures, Kindred and Meltwind. Emerging from a decade of research excellence, we bring together **international scientific and medical leaders across oncology, immunology and vaccine development**. Our first generation of vaccines deliver **80% survival and the prevention of metastases**, in preclinical trials. This is important because metastases have been shown to cause 70-90% of cancer deaths. With Innovate UK's support, we are **progressing our lead therapy into an exciting proof of concept human clinical trial**, to protect patients after surgical resection of their tumour. Infinitopes is able to deliver these unusually high levels of protection, because our technologies combine **accurate tumour target identification with high efficiency delivery, to durably stimulate patients' immunity against their cancers**. New high sensitivity technologies are emerging with the **potential to revolutionise tumour target discovery**. Our Enhanced Precision Immunomics Cancer antigen DISCOvery **(EPIC DISCO) project proposes to conduct experimental development, to systematically evaluate and improve the key steps in antigen discovery**, in order to leverage maximal benefit from these new systems. We will also build highly **accurate immunopeptidome tumour maps for 4-5 target indications, including common cancers of childhood and adolescence, sarcoma and glioblastoma, and adult cancers** of high unmet need. This project cements Infinitopes' **leadership of immuno-oncology therapeutics, directly supporting tens of new highly skilled jobs**, where we can continue to contribute to Britain's world leading life sciences ecosystem, while unlocking substantial partnerships with Big Pharma and biotech collaborators. Infinitopes' mission is to progressively enhance our discovery and vector technology platforms, **to enable precisely targeted treatment of high unmet cancers, affordably and without side effects**.

Oesophageal cancer is the 5th cause of cancer death in the UK and prioritised as one of the four tumour types with the highest unmet clinical need according to Cancer Research UK. In particular, cancer metastases, or the spread of cancer to other critical body parts such as the liver, significantly reduces survival rates of patients. **_Therefore, early detection and intervention is crucial to prevent and/or significantly delay the onset of metastases._** Sadly, the UK does not report 5-year Stage 4 survival statistics. There is a very high mortality associated with oesophageal cancer metastases. In the US, survival rate is less than 4.6% (SEER, 2019). Approximately 50% of oesophageal cancer diagnoses are eligible for surgery, but surgery is highly invasive, risky and affects patients' quality of life. Crucially, surgery does not prevent metastases. The other 50% of patients currently receive chemotherapy, which is _**aggressive,**_ causing several side-effects, including weakening the immune system. Other technologies (i.e. checkpoint inhibitors, CAR-T therapy and other similar cell therapies) have their own _**limitations in terms of efficacy, delivery and especially cost.**_ Cancer vaccines that can generate high-magnitude immune responses directed to tumour-specific antigens represent promising novel cancer therapies. **_However, existing approaches have failed to succeed_** due to poor treatment regimens, suboptimal vaccine delivery platforms and poor selection of tumour antigens. _**Infinitopes, a biotech spinout from Oxford University, has developed a highly novel, patented anti-metastatic vaccine that can be combined with standard chemotherapy to prevent**_ **_metastases._** Preclinical studies have demonstrated our vaccine can confer unprecedented long-term protection and absolutely suppression of metastases in multiple tumour models. With Innovate UK support, Infinitopes will be able to take the next step in our journey, which is to complete the First-In-Human clinical trial in oesophageal cancer patients. As a biotech spinout from the University of Oxford, **_Infinitopes is a unique collaboration of world-leading cancer doctors, immunologists & vaccine experts_** who possess the expertise and capability to successfully deliver this project. If successful, Infinitopes' technology enjoys enormous potential to transform the lives of millions of patients globally, create further employment opportunities and strengthen the UK biomedical industrial base.